Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner

被引:7
作者
Foehr, Karl Josef [1 ]
Nastos, Ariadni [1 ]
Fauler, Michael [2 ]
Zimmer, Thomas [3 ]
Jungwirth, Bettina [1 ]
Messerer, David Alexander Christian [1 ]
机构
[1] Univ Hosp Ulm, Dept Anesthesiol & Intens Care Med, Ulm, Germany
[2] Ulm Univ, Dept Gen Physiol, Ulm, Germany
[3] Univ Hosp Jena, Inst Physiol, Jena, Germany
来源
FRONTIERS IN PHARMACOLOGY | 2021年 / 12卷
关键词
atomoxetine; hNav1; 5; cardiotoxicity; antiarrhythmic; patch clamp; attention-deficit; hyperactivity disorder;
D O I
10.3389/fphar.2021.622489
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Atomoxetine, a neuroactive drug, is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). It is primarily known as a high affinity blocker of the noradrenaline transporter, whereby its application leads to an increased level of the corresponding neurotransmitter in different brain regions. However, the concentrations used to obtain clinical effects are much higher than those which are required to block the transporter system. Thus, off-target effects are likely to occur. In this way, we previously identified atomoxetine as blocker of NMDA receptors. As many psychotropic drugs give rise to sudden death of cardiac origin, we now tested the hypothesis whether atomoxetine also interacts with voltage-gated sodium channels of heart muscle type in clinically relevant concentrations. Electrophysiological experiments were performed by means of the patch-clamp technique at human heart muscle sodium channels (hNav1.5) heterogeneously expressed in human embryonic kidney cells. Atomoxetine inhibited sodium channels in a state- and use-dependent manner. Atomoxetine had only a weak affinity for the resting state of the hNav1.5 (Kr: similar to 120 mu M). The efficacy of atomoxetine strongly increased with membrane depolarization, indicating that the inactivated state is an important target. A hallmark of this drug was its slow interaction. By use of different experimental settings, we concluded that the interaction occurs with the slow inactivated state as well as by slow kinetics with the fast-inactivated state. Half-maximal effective concentrations (2-3 mu M) were well within the concentration range found in plasma of treated patients. Atomoxetine also interacted with the open channel. However, the interaction was not fast enough to accelerate the time constant of fast inactivation. Nevertheless, when using the inactivation-deficient hNav1.5_I408W_L409C_A410W mutant, we found that the persistent late current was blocked half maximal at about 3 mu M atomoxetine. The interaction most probably occurred via the local anesthetic binding site. Atomoxetine inhibited sodium channels at a similar concentration as it is used for the treatment of ADHD. Due to its slow interaction and by inhibiting the late current, it potentially exerts antiarrhythmic properties.
引用
收藏
页数:14
相关论文
共 36 条
[11]   AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 [J].
Hiemke, C. ;
Baumann, P. ;
Bergemann, N. ;
Conca, A. ;
Dietmaier, O. ;
Egberts, K. ;
Fric, M. ;
Gerlach, M. ;
Greiner, C. ;
Gruender, G. ;
Haen, E. ;
Havemann-Reinecke, U. ;
Sirot, E. Jaquenoud ;
Kirchherr, H. ;
Laux, G. ;
Lutz, U. C. ;
Messer, T. ;
Mueller, M. J. ;
Pfuhlmann, B. ;
Rambeck, B. ;
Riederer, P. ;
Schoppek, B. ;
Stingl, J. ;
Uhr, M. ;
Ulrich, S. ;
Waschgler, R. ;
Zernig, G. .
PHARMACOPSYCHIATRY, 2011, 44 (06) :195-235
[12]   V102862 (Co 102862): a potent, broad-spectrum state-dependent blocker of mammalian voltage-gated sodium channels [J].
Ilyin, VI ;
Hodges, DD ;
Whittemore, ER ;
Carter, RB ;
Cai, SX ;
Woodward, RM .
BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (06) :801-812
[13]   Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation [J].
Jarecki, Brian W. ;
Sheets, Patrick L. ;
Jackson, James O., II ;
Cummins, Theodore R. .
JOURNAL OF PHYSIOLOGY-LONDON, 2008, 586 (17) :4137-4153
[14]   Fast- or Slow-inactivated State Preference of Na+ Channel Inhibitors: A Simulation and Experimental Study [J].
Karoly, Robert ;
Lenkey, Nora ;
Juhasz, Andras O. ;
Vizi, E. Sylvester ;
Mike, Arpad .
PLOS COMPUTATIONAL BIOLOGY, 2010, 6 (06) :1-13
[15]   Inhibition of G-Protein-Activated Inwardly Rectifying K+ Channels by the Selective Norepinephrine Reuptake Inhibitors Atomoxetine and Reboxetine [J].
Kobayashi, Toru ;
Washiyama, Kazuo ;
Ikeda, Kazutaka .
NEUROPSYCHOPHARMACOLOGY, 2010, 35 (07) :1560-1569
[16]   Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial [J].
Kratochvil, CJ ;
Heiligenstein, JH ;
Dittmann, R ;
Spencer, TJ ;
Biederman, J ;
Wernicke, J ;
Newcorn, JH ;
Casat, C ;
Milton, D ;
Michelson, D .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2002, 41 (07) :776-784
[17]   Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones [J].
Kuo, CC ;
Lu, L .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (06) :1231-1238
[18]   Use-dependent block by lidocaine but not amitriptyline is more pronounced in tetrodotoxin (TTX)-resistant Nav1.8 than in TTX-sensitive Na+ channels [J].
Leffler, Andreas ;
Reiprich, Anne ;
Mohapatra, Durga P. ;
Nau, Carla .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 320 (01) :354-364
[19]   The mechanism of activity-dependent sodium channel inhibition by the antidepressants fluoxetine and desipramine [J].
Lenkey, N. ;
Karoly, R. ;
Kiss, J. P. ;
Szasz, B. K. ;
Vizi, E. S. ;
Mike, A. .
MOLECULAR PHARMACOLOGY, 2006, 70 (06) :2052-2063
[20]   Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations [J].
Ludolph, Andrea G. ;
Udvardi, Patrick T. ;
Schaz, Ulrike ;
Henes, Carolin ;
Adolph, Oliver ;
Weigt, Henry U. ;
Fegert, Joerg M. ;
Boeckers, Tobias M. ;
Foehr, Karl J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (02) :283-291